Covered recipient · General Payments record
RONALD TODD PLOTT
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$19,232.86
111 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $14,800.00 | 5 |
| Food and Beverage | $2,479.38 | 100 |
| Travel and Lodging | $1,854.48 | 5 |
| Education | $99.00 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES INC. | $17,325.49 | 27 |
| AbbVie Inc. | $293.43 | 14 |
| Janssen Biotech, Inc. | $259.24 | 16 |
| EPI Health, LLC | $205.58 | 1 |
| Galderma Laboratories, L.P. | $201.73 | 7 |
| Almirall LLC | $141.11 | 2 |
| GENZYME CORPORATION | $129.21 | 7 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $117.66 | 8 |
| Regeneron Healthcare Solutions, Inc. | $100.00 | 5 |
| UCB, Inc. | $97.57 | 3 |
| Novartis Pharmaceuticals Corporation | $68.43 | 4 |
| PFIZER INC. | $64.61 | 4 |
| Lilly USA, LLC | $58.67 | 3 |
| Genentech USA, Inc. | $34.59 | 2 |
| VYNE Pharmaceuticals Inc. | $30.50 | 2 |
| Incyte Corporation | $25.46 | 1 |
| Misonix Inc | $24.90 | 2 |
| Medimetriks Pharmaceuticals, Inc. | $24.67 | 1 |
| LEO Pharma Inc. | $18.22 | 1 |
| Medtronic, Inc. | $11.79 | 1 |
Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RONALD TODD PLOTT
NPI 1558569087 · CMS profile ID 206083
Allopathic & Osteopathic Physicians / Dermatology
FORT WORTH, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1558569087?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RONALD TODD PLOTT, NPI 1558569087, CMS profile ID 206083. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558569087?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). RONALD TODD PLOTT, NPI 1558569087, CMS profile ID 206083. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558569087?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- RONALD TODD PLOTT, NPI 1558569087, CMS profile ID 206083, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1558569087?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
111 matching records · $19,232.86 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–111 of 111.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $24.62 | 02/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843475089 | CMS |
| Janssen Biotech, Inc. | $14.67 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788385135 | CMS |
| AbbVie Inc. | $21.36 | 02/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795662241 | CMS |
| PFIZER INC. | $21.18 | 02/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832743291 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $24.22 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851924609 | CMS |
| Medtronic, Inc. | $11.79 | 02/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815645235 | CMS |
| Janssen Biotech, Inc. | $17.73 | 02/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788385133 | CMS |
| AbbVie Inc. | $19.18 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795662235 | CMS |
| Galderma Laboratories, L.P. | $1.54 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855296331 | CMS |
| AbbVie Inc. | $21.03 | 01/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795662229 | CMS |
| Janssen Biotech, Inc. | $13.83 | 01/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788385131 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,003,105.98 | 71 |
| PY2024 | Recipient | $1,688.79 | 10 |
| PY2024 | Principal investigator | $662,593.88 | 19 |
| PY2021 | Principal investigator | $3,824.03 | 5 |
| PY2019 | Principal investigator | $81,125.69 | 7 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
71 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $47,200.00 | 12/15/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226132105 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,284.10 | 11/24/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226132101 |
| Principal investigator 1 | PFIZER INC. | $800.00 | 11/19/2025 | Non-covered Recipient Entity Stryde Consulting | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228739577 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $68,400.00 | 11/17/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226132098 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,031.70 | 10/20/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226132095 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,100.00 | 10/14/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226132088 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $41,000.00 | 09/22/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226132084 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,704.10 | 09/15/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226132079 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 09/03/2025 | Non-covered Recipient Entity Stryde Consulting | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228712986 |
| Principal investigator 1 | PFIZER INC. | $1,050.00 | 09/03/2025 | Non-covered Recipient Entity Stryde Consulting | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228712988 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 09/03/2025 | Non-covered Recipient Entity Stryde Consulting | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228713072 |
| Principal investigator 1 | PFIZER INC. | $2,100.00 | 09/03/2025 | Non-covered Recipient Entity Stryde Consulting | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228713074 |
| Principal investigator 1 | PFIZER INC. | $10,000.00 | 09/03/2025 | Non-covered Recipient Entity Stryde Consulting | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228713370 |
| Principal investigator 1 | PFIZER INC. | $350.00 | 09/03/2025 | Non-covered Recipient Entity Stryde Consulting | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228713456 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $32,400.00 | 08/25/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226132075 |
| Principal investigator 1 | PFIZER INC. | $2,290.00 | 08/11/2025 | Non-covered Recipient Entity Stryde Consulting | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228713368 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,161.70 | 08/11/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226132057 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,987.00 | 08/11/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226132061 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,976.00 | 08/11/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226132066 |
| Principal investigator 1 | Amgen Inc. | $7,000.00 | 08/01/2025 | Non-covered Recipient Entity STRYDE CONSULTING LLC STRYDE RESEARCH | A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) | No dispute reported | 06/30/2026 | 1246648802 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $32,600.00 | 07/14/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226132006 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,485.60 | 07/14/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226132008 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,153.50 | 07/14/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226132011 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,031.70 | 07/07/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226132035 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,414.20 | 07/02/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226132016 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $32,600.00 | 06/16/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226131953 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,537.80 | 06/16/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131981 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,481.40 | 06/09/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226131950 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,499.02 | 05/19/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226131994 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $64,300.00 | 05/19/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226132002 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,664.50 | 05/12/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131936 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,714.20 | 05/05/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226131907 |
| Principal investigator 1 | Amgen Inc. | $59,170.41 | 04/24/2025 | Non-covered Recipient Entity STRYDE CONSULTING LLC STRYDE RESEARCH | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246648806 |
| Principal investigator 1 | Amgen Inc. | $29,128.00 | 04/24/2025 | Non-covered Recipient Entity STRYDE CONSULTING LLC STRYDE RESEARCH | A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) | No dispute reported | 06/30/2026 | 1246648810 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $49,200.00 | 04/14/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226131909 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,205.40 | 04/07/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226131897 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $21,786.40 | 04/02/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226131859 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,475.90 | 04/02/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131886 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,307.55 | 04/02/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226131894 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,574.20 | 03/24/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226131836 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $34,400.00 | 03/24/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226131856 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $25,486.50 | 03/10/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131870 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,090.70 | 03/10/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226131890 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,000.00 | 02/24/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131735 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,558.00 | 02/24/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131817 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,939.00 | 02/24/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131873 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,625.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131723 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,000.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131727 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,250.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131732 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,125.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131741 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,375.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131745 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,125.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131749 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,000.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131754 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $23,000.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226131758 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $875.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131761 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,000.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131766 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $625.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131770 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $750.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131779 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $375.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131785 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,325.00 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226131790 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,895.50 | 02/18/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131882 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,063.40 | 02/10/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226131877 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,900.00 | 02/04/2025 | Non-covered Recipient Entity Skin Care Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145024 |
| Principal investigator 1 | Amgen Inc. | $14,000.00 | 01/30/2025 | Non-covered Recipient Entity STRYDE RESEARCH EPIPHANY DERMATOLOGY | A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) | No dispute reported | 06/30/2026 | 1246648814 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 01/27/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131802 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,550.00 | 01/27/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131807 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $750.00 | 01/27/2025 | Non-covered Recipient Entity Stryde Consulting Llc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226131813 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,385.00 | 01/21/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226131775 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $26,400.00 | 01/21/2025 | Non-covered Recipient Entity Stryde Consulting Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226131793 |
| Principal investigator 1 | Amgen Inc. | $53,321.99 | 01/07/2025 | Non-covered Recipient Entity EPIPHANY DERMATOLOGY | A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) | No dispute reported | 06/30/2026 | 1246641271 |
| Principal investigator 1 | Amgen Inc. | $53,251.51 | 01/02/2025 | Non-covered Recipient Entity STRYDE RESEARCH EPIPHANY DERMATOLOGY | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246648818 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2022 | Amount invested | $0.00 | 1 |
| PY2022 | Value of interest | $61,680.00 | 1 |
| PY2021 | Amount invested | $275,000.00 | 1 |
| PY2021 | Value of interest | $102,750.00 | 1 |
| PY2020 | Amount invested | $275,000.00 | 1 |
| PY2020 | Value of interest | $99,000.00 | 1 |
| PY2019 | Amount invested | $175,000.00 | 1 |
| PY2019 | Value of interest | $58,000.00 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
4 records · PY2019–2022
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2022 | Medimetriks Pharmaceuticals, Inc. | $0.00 | $61,680.00 | Dr. Platt has 75,000 shares at $0.8224 per share. Cert.#(s) 134 (25,000 sh); 141 (25,000 sh); 173 (25,000 sh). | Physician Covered Recipient | No dispute reported | 06/30/2026 | 885272171 |
| PY2021 | Medimetriks Pharmaceuticals, Inc. | $275,000.00 | $102,750.00 | HCP OWNS 75,000 SHARES. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 803531619 |
| PY2020 | Medimetriks Pharmaceuticals, Inc. | $275,000.00 | $99,000.00 | Shares of Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 746592249 |
| PY2019 | Medimetriks Pharmaceuticals, Inc. | $175,000.00 | $58,000.00 | Shares of Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 703279819 |